SMO

Across TCGA pan-cancer cohorts, SMO mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SMO data layer compared with 21 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SMO mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SMO expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CCRCC, UCEC, and LUAD are the cancer types where SMO mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.684	1.000	.016	8	view →
UCEC	DFS	Tertile	All	1.000	0.639	.031	2	view →
LUAD	DFS	Tertile	II,III,IV	0.329	0.905	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SMO–CCRCC (DFS)

Open the CCRCC breakdown →